- Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics<figure><div><img src="https://imgproxy.divecdn.com/tzaRDX3CbhReY4UgPVj2iCgN5MzQ9V_AQf0Jo1lvCvY/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy05OTEzMjk1ODQuanBn.…BioPharma Dive · 11d ago↗ source
- ‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D winsA string of recent wins on the frontiers of novel drug development could mean that a homegrown innovation industry is within reach.Fierce Biotech · 11d ago↗ source
- Chutes & Ladders—Cue lines up new CMO and research headCue Biopharma is tapping in a new chief medical officer and head of R&D in Dominic Borie, M.D., Ph.D., a physician-scientist with over two decades of industry experience.